Article
Targeting USP2 induces degradation of PML-RARα with or without drug-resistant mutations in acute promyelocytic leukemia
2025-05-14
Abstract excerpt
Despite the high efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in treating acute promyelocytic leukemia (APL), approximately 10-20% of patients develop drug resistance due to mutations in PML-RARα and other factors. Here, it is demonstrated that inhibiting USP2 with ML364 or silencing USP2 reduces PML-RARα protein levels in both ATRA-sensitive and -resistant APL cells, an effect reversed by...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 64628228-792a-572d-b955-63c18012f40a
- DOI
- 10.1101/2025.05.11.653221
